24 results
Thumbnail

D2.191 - Tolerogenic Immune Shifts Following PQ Grass 27600 SU Treatment in Seasonal Allergic Rhinitis

Thumbnail

D2.194 - Norovirus-Like Particles as Novel Carriers of Hypoallergenic Artemisia vulgaris Allergen Art v 3 for Allergen-Specific Immunotherapy

Thumbnail

D2.181 - Managing asthma and allergies during the Russo-Ukrainian war: The damage assessment

Thumbnail

D2.182 - Mass Spectrometric Identification of Allergens from Dermatophagoides spp. and Blomia tropicalis in Native, Depigmented and Depigmented-Polymerized Extracts

Thumbnail

D2.183 - Differential Sensitization to Goat and Sheep Milk with Partial Tolerance to Cow’s Milk

Thumbnail

D2.184 - Sensitization profile to vespid venom: limitations in clinical practice

Thumbnail

D2.186 - In vivo and ex vivo evaluation of the immunological responses induced by a grass depigmented-polymerized allergenic extract in dogs

Thumbnail

D2.187 - Are Component-Based Skin Tests Reliable? Correlation between Skin Prick Testing and Specific IgE to Der p 1, Der p 2 and Der p 23

Thumbnail

D2.188 - Spectrum of Sensitization to Respiratory Allergens in Patients in the Republic of Kazakhstan

Thumbnail

D2.190 - Evaluation of a commercially available Birch Pollen Extract for its suitability in Nasal Allergen Challenges: Feasibility and Dose-Response Assessment

Thumbnail

D2.192 - Comparison of the Multiplex ALEX Method and Single-Plex ImmunoCAP Method in the Diagnosis of Seasonal Allergic Rhinitis in Adults Caused by Birch Pollen

Thumbnail

D2.193 - Real-World Effectiveness of Allergen Immunotherapy in Polysensitized Patients: A Retrospective Study of 260 Cases

Thumbnail

D2.195 - AIT prescription drivers: a cluster analysis of data from the CHOICE survey

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial